Latest updates on our clinical progress, corporate milestones, and scientific presentations.
Edison Innovations, a Dominion Harbor Company, and Illuminare Biotechnologies have memorialized and strengthened their licensing agreement, supporting the upcoming Phase II clinical trial of Illuminare-1 (rizedisben). Protected by Edison's patent portfolio, Illuminare-1 potentially represents a major breakthrough in intraoperative nerve visualization.
Q&A with Stewart McCallum,MD, FACS, CMO of Illuminare Biotechnologies, about how a novel myelin-binding fluorophore helps surgeons see nerves clearly during operations.
Host Rick Greene, MD, FACS, talks with Samuel A. Gold, MD, from the urology service in the Department of Surgery at Memorial Sloan Cancer Center in New York, New York, about using intraoperative fluorescence to illuminate nerve structures during robotic-assisted prostatectomy
Featured coverage on the potential of our new imaging technique to reduce side effects in prostate cancer surgery.
Official press release detailing the successful outcomes of our first-in-human study.
MSKCC press release highlighting our collaboration and innovative imaging solution.
Presentation of our novel myelin-binding fluorophore for intraoperative fluorescent imaging of nerve structures.
Milestone achievement marking the beginning of clinical validation for our novel nerve visualization fluorophore.
Regulatory clearance paving the way for First-In-Human trials.